The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Management of borderline resectable non-oncogene driven NSCLC
Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the management of borderline resectable, non-oncogene driven stage III non-small cell lung cancer (NSCLC) from a radio-oncology perspective, highlighting the blurring of boundaries between surgical and non-surgical approaches due to the introduction of immunotherapy. The use of induction immunotherapy followed by chemoradiation can lead to approximately 90% of patients receiving curative intent local therapy, with a high chance of survival and cure, although strategies are needed to minimize adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
